UTHR Q4 2024 Earnings — United Therapeutics Corporation Revenue & Financial Results | Market Cap Arena

UTHRUnited Therapeutics Corporation

$24B

Q4 2024 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$736M+19.7% YoY

Gross Profit

$660M89.7% margin

Operating Income

$358M48.6% margin

Net Income

$301M40.9% margin

EPS (Diluted)

$6.19

QoQ Revenue Growth

-1.7%

Cash Flow

Operating Cash Flow

$341M

Free Cash Flow

$255M

Stock-Based Comp.

$27M

Balance Sheet

Total Assets

$7.4B

Total Liabilities

$920M

Stockholders' Equity

$6.4B

Cash & Equivalents

$1.7B

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$736M	$615M	+19.7%
Gross Profit	$660M	$544M	+21.4%
Operating Income	$358M	$260M	+37.5%
Net Income	$301M	$217M	+38.8%

Revenue Segments

Tyvaso

$416M57%

Remodulin

$135M18%

Orenitram

$108M15%

Unituxin

$68M9%

Product and Service, Other

$6M1%

Adcirca

$5M1%

Geographic Segments

UNITED STATES

$706M96%

Non-US

$30M4%